Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Mammary Carcinoma|Metastatic Breast Cancer
Interventions: DRUG: Capecitabine|OTHER: Endocrine-therapy|OTHER: MammoPrint ® and BluePrint assays
Sponsor: Sonya Reid
Collaborators: Agendia|Susan G. Komen Breast Cancer Foundation